Literature DB >> 30074218

Expression of MMIF, HIF-1α and VEGF in Serum and Endometrial Tissues of Patients with Endometriosis.

Fan Zhang1, Xiao-Ling Liu1, Wan Wang1, Hong-Ling Dong1, Yu-Fang Xia1, Li-Ping Ruan1, Li-Ping Liu2.   

Abstract

The aim of this study was to investigate the expression of macrophage migration inhibitory factor (MMIF), hypoxia-inducible factor-1 a (HIF-1α) and vascular endothelial growth factor (VEGF) in the serum and endometrial tissues of patients with endometriosis (EM) and the clinical significance. Eighty EM patients [American Reproductive Association stage I (n=20), stage II (n=22), stage III (n=21) and stage IV (n=17)] were enrolled and divided into mild (10-14 points, n=28), moderate (16-24 points, n=27) and severe (26-30 points, n=25) dysmenorrhea groups. The control group included 40 healthy women of childbearing age who underwent routine healthcare examinations in the enrolment period. The expression of MMIF, HIF-1α and VEGF in the serum and endometrial tissues was measured by enzyme-linked immunosorbent assay and Western blotting, respectively. Meanwhile, the sensitivity and specificity of serum MMIF, HIF-1α, and VEGF when separately used as single indexes or jointly used as one index were examined as well. The results showed that serum concentrations of MMIF, HIF-1α, and VEGF were significantly higher in EM patients than in controls (P<0.05). The expression of all three proteins in both serum and endometrial tissues increased significantly with the R-AFS stage (P<0.05) and with dysmenorrheal severity (P<0.05). The sensitivity and specificity of the combined detection of serum MMIF, HIF-1α, and VEGF levels were significantly higher than those of single index detection (P<0.05). In conclusion, the expression of MMIF, HIF-1α, and VEGF in the serum and endometrial tissues may be used to assess the stage of EM and the severity of dysmenorrhea. Combined evaluation of MMIF, HIF-1α, and VEGF significantly improves the diagnostic sensitivity and specificity.

Entities:  

Keywords:  diagnosis; endometriosis; hypoxia-inducible factor-1α; macrophage migration inhibitory factor; vascular endothelial growth factor

Mesh:

Substances:

Year:  2018        PMID: 30074218     DOI: 10.1007/s11596-018-1906-1

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  30 in total

1.  Inhibition of dual specificity phosphatase-2 by hypoxia promotes interleukin-8-mediated angiogenesis in endometriosis.

Authors:  Kuei-Yang Hsiao; Ning Chang; Shih-Chieh Lin; Yo-Hua Li; Meng-Hsing Wu
Journal:  Hum Reprod       Date:  2014-10-14       Impact factor: 6.918

2.  Hypoxia induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human endometrial cells.

Authors:  Ki Hyung Kim; Hye Young Kim; Hyeong Hoe Kim; Kyu Sup Lee; Jaehun Cheong
Journal:  Mol Hum Reprod       Date:  2011-05-25       Impact factor: 4.025

Review 3.  Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.

Authors:  Rupert Courtnay; Darleen C Ngo; Neha Malik; Katherine Ververis; Stephanie M Tortorella; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

Review 4.  The patient-centeredness of endometriosis care and targets for improvement: a systematic review.

Authors:  Eline A F Dancet; Silke Apers; Jan A M Kremer; Willianne L D M Nelen; Walter Sermeus; Thomas M D'Hooghe
Journal:  Gynecol Obstet Invest       Date:  2014-05-22       Impact factor: 2.031

5.  Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells.

Authors:  Nina Baron; Oliver Deuster; Carmen Noelker; Carsten Stüer; Herwig Strik; Carlo Schaller; Richard Dodel; Bernhard Meyer; Michael Bacher
Journal:  J Neurosci Res       Date:  2011-02-24       Impact factor: 4.164

6.  Macrophage migration inhibitory factor: a regulator of MMP13 and inflammation in titanium particles-stimulated air pouch in vivo.

Authors:  Xiaoyun Pan; Xin Mao; Tao Cheng; Xianlong Zhang
Journal:  Mol Cell Biochem       Date:  2011-05-29       Impact factor: 3.396

7.  Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.

Authors:  Amal M El-Naggar; Chansey J Veinotte; Hongwei Cheng; Thomas G P Grunewald; Gian Luca Negri; Syam Prakash Somasekharan; Dale P Corkery; Franck Tirode; Joan Mathers; Debjit Khan; Alastair H Kyle; Jennifer H Baker; Nancy E LePard; Steven McKinney; Shamil Hajee; Momir Bosiljcic; Gabriel Leprivier; Cristina E Tognon; Andrew I Minchinton; Kevin L Bennewith; Olivier Delattre; Yuzhuo Wang; Graham Dellaire; Jason N Berman; Poul H Sorensen
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

8.  Peritoneal cytokines and adhesion formation in endometriosis: an inverse association with vascular endothelial growth factor concentration.

Authors:  Ewa Barcz; Łukasz Milewski; Piotr Dziunycz; Paweł Kamiński; Rafał Płoski; Jacek Malejczyk
Journal:  Fertil Steril       Date:  2012-04-28       Impact factor: 7.329

9.  Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis.

Authors:  Hui Xu; Tao Zhang; Gene Chi Wai Man; Katie E May; Christian M Becker; Tina N Davis; Andrew L Kung; Amy E Birsner; Robert J D'Amato; Alice Wai Yee Wong; Chi Chiu Wang
Journal:  Angiogenesis       Date:  2013-01-19       Impact factor: 9.596

Review 10.  Cellular and molecular basis for endometriosis-associated infertility.

Authors:  Julie A W Stilley; Julie A Birt; Kathy L Sharpe-Timms
Journal:  Cell Tissue Res       Date:  2012-09       Impact factor: 5.249

View more
  8 in total

1.  HIF-1α upregulation exerts the antagonistic effect against angiogenesis inhibition in manganese deficiency-induced tibial dyschondroplasia of broiler chicks.

Authors:  Lu Lu; Cong Jin; Peng-Fei Dong; Zhen-Yong Wang
Journal:  Vet Res Commun       Date:  2022-07-15       Impact factor: 2.816

Review 2.  Inflammatory MicroRNAs and the Pathophysiology of Endometriosis and Atherosclerosis: Common Pathways and Future Directions Towards Elucidating the Relationship.

Authors:  Zubeen D Azari; Fatimah Aljubran; Warren B Nothnick
Journal:  Reprod Sci       Date:  2022-04-27       Impact factor: 2.924

3.  Altered gene expression of VEGF, IGFs and H19 lncRNA and epigenetic profile of H19-DMR region in endometrial tissues of women with endometriosis.

Authors:  Sedigheh Kamrani; Elham Amirchaghmaghi; Firouzeh Ghaffari; Maryam Shahhoseini; Kamran Ghaedi
Journal:  Reprod Health       Date:  2022-04-22       Impact factor: 3.355

4.  Identification of differentially expressed genes and signaling pathways involved in endometriosis by integrated bioinformatics analysis.

Authors:  Fang-Fang Dai; An-Yu Bao; Bing Luo; Zi-Hang Zeng; Xiao-Li Pu; Yan-Qing Wang; Li Zhang; Shu Xian; Meng-Qin Yuan; Dong-Yong Yang; Shi-Yi Liu; Yan-Xiang Cheng
Journal:  Exp Ther Med       Date:  2019-11-18       Impact factor: 2.447

5.  Utilizing network pharmacology and molecular docking to explore the underlying mechanism of Guizhi Fuling Wan in treating endometriosis.

Authors:  Haoxian Wang; Gang Zhou; Mingyan Zhuang; Wei Wang; Xianyun Fu
Journal:  PeerJ       Date:  2021-04-02       Impact factor: 2.984

6.  A network pharmacology approach to explore active compounds and pharmacological mechanisms of a patented Chinese herbal medicine in the treatment of endometriosis.

Authors:  Yan Wu; Yuhang Zhu; Ningning Xie; Hui Wang; Fangfang Wang; Jue Zhou; Fan Qu
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

7.  MiodesinTM Positively Modulates the Immune Response in Endometrial and Vaginal Cells.

Authors:  Carlos Rocha Oliveira; Hudson Polonini; Maria Cristina Marcucci; Rodolfo P Vieira
Journal:  Molecules       Date:  2022-01-25       Impact factor: 4.411

8.  Clues for Improving the Pathophysiology Knowledge for Endometriosis Using Serum Micro-RNA Expression.

Authors:  Yohann Dabi; Stéphane Suisse; Ludmila Jornea; Delphine Bouteiller; Cyril Touboul; Anne Puchar; Emile Daraï; Sofiane Bendifallah
Journal:  Diagnostics (Basel)       Date:  2022-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.